Dollar Tree (DLTR) is expected to post third-quarter results on Nov 29, Thursday, before the opening bell. The Street expects earnings $1.14 a share on revenue of $5.55 billion for the period.
The trade war between the Trump administration and China have caught up to the retailer, as fresh taxes on imports worth $200 billion have resulted in price escalation affecting the arrival of low-priced consumer items. While usually tariffs were slapped on industrial goods imported from the Asian country, this new predicament has forced Dollar Tree and its peers to sell the products at old prices for losses or pull them from the shelves.
Other discount store operators like Dollar General (DG) are no different due to the new tariff regime. If the taxes are not rolled back, profitability will be under pressure in the long term, resulting in headcount reduction and store closures.
However, the market has hopes for Dollar Tree.
Many big-time investors have recently increased their holdings in Dollar Tree. In the third quarter, Price Capital Management Inc. added $106,000 worth of shares, while SRS Capital Advisors ramped up its holdings by 250% with an additional 1,009 shares. Institutional investors now own 92.83% stock, indicating a possible long-term growth.
In its second quarter that Dollar Tree reported in August, revenue and net earnings showed impressive growth, while same-store sales were a let down in both Dollar Tree and Family Dollar arms. The results missed estimates, which triggered a short slump in shares.
Investors will be looking for impressive numbers this quarter, especially comparable sales as the retail market is on scrutiny after the wave of e-commerce led by Amazon (AMZN) and Alibaba (BABA). While these online players are looking to diversify to brick-and-mortar stores, it will be amusing to see how thrift retailers will position themselves to remain competitive and provide value to its customers and investors.
Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
